{"entity":{"id":"rasburicase","kind":"drug","name":"Rasburicase","aka":["Fasturtec","Recombinant urate oxidase"],"tldr":"Rasburicase (Elitek) is an enzyme infusion that rapidly dissolves the uric acid released when large numbers of leukaemia or lymphoma cells die at the start of treatment, protecting the kidneys from tumour lysis syndrome.","summary":"Rasburicase was approved by the FDA in July 2002 for initial management of plasma uric acid in children (adults added 2009) with leukaemia, lymphoma or solid tumours receiving therapy expected to cause tumour lysis, on randomised trials against allopurinol in which uric acid normalised within four hours in almost all patients; the EU authorised Fasturtec in 2001. It is standard for high-risk tumour lysis syndrome (Burkitt lymphoma, high-count ALL and AML, venetoclax ramp-up in CLL with bulky disease), often as a single dose rather than the labelled five days. Haemolysis and methaemoglobinaemia in G6PD deficiency, anaphylaxis and interference with uric acid assays (samples must be chilled) carry boxed warnings.","status":"approved","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Rasburicase","links":[{"label":"US label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=rasburicase"},{"label":"NCI drug page","url":"https://www.cancer.gov/about-cancer/treatment/drugs/rasburicase"},{"label":"EPAR (Fasturtec)","url":"https://www.ema.europa.eu/en/medicines/human/EPAR/fasturtec"}],"tags":["nci-list","supportive"],"related":[],"cancers":["all-leukemia","aml","dlbcl","cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["sanofi"],"institutions":[],"pathways":[],"terms":[],"trials":["nct00199043","nct00057811","nct01200485"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Elitek","modality":"Recombinant enzyme (urate oxidase)","supportive":true,"mechanism":"Recombinant Aspergillus urate oxidase that converts uric acid to allantoin, which is five to ten times more soluble and readily excreted, lowering plasma uric acid within hours.","approvals":[{"region":"US","year":2002,"indication":"Initial management of plasma uric acid in paediatric patients with leukaemia, lymphoma or solid tumours at risk of tumour lysis (adults added 2009)"},{"region":"EU","year":2001,"indication":"Treatment and prophylaxis of acute hyperuricaemia in haematological malignancy with high tumour burden (Fasturtec)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rasburicase/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"}],"trial":[{"id":"nct01200485","kind":"trial","name":"Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2","route":"/trials/nct01200485/"},{"id":"nct00057811","kind":"trial","name":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","route":"/trials/nct00057811/"},{"id":"nct00199043","kind":"trial","name":"Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma","route":"/trials/nct00199043/"}],"term":[{"id":"lymphoma-tx-tumour-lysis","kind":"term","name":"Tumour lysis syndrome in lymphoma: who is at risk, and rasburicase","route":"/terms/lymphoma-tx-tumour-lysis/"}],"target":[{"id":"xdh","kind":"target","name":"Xanthine oxidase (XDH)","route":"/targets/xdh/"}]}}